From: A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms (“KHENERGYC”)
Population
Dose (mg) per administration (BID)
Neonates (0–28 days)
2
Infants (1–2.5 months)
4
Infants (2.5–12 months)
12
Toddlers (1–2 years)
23
Young Children (2–6 years)
33
Middle-Aged Children (6–12 Years)
55
Adolescents (12–17 years)
80